STOCK TITAN

WUXI BIOLOGICS UNSP/ADR - WXXWY STOCK NEWS

Welcome to our dedicated page for WUXI BIOLOGICS UNSP/ADR news (Ticker: WXXWY), a resource for investors and traders seeking the latest updates and insights on WUXI BIOLOGICS UNSP/ADR stock.

WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end solutions for biologics drug development. They offer efficient and cost-effective services for discovering, developing, and manufacturing biologics, from concept to commercialization. With experienced leadership and expert scientists, WuXi Biologics has contributed to numerous successful projects, including the discovery of novel therapeutic product candidates and the development of state-of-the-art technologies like WuXiBody™ and WuXiaADCC PLUSTM. They are committed to sustainability and ESG leadership, exemplified by their innovative approaches and industry recognition.

Rhea-AI Summary
WuXi Biologics (2269.HK) has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, recognized as a sustainability leader by S&P Global. The company was ranked number one in its sector in the Corporate Sustainability Assessment (CSA). WuXi Biologics CEO, Dr. Chris Chen, expressed pride in the achievement, emphasizing the company's commitment to enhancing ESG capabilities and sustainable growth. WuXi Biologics has demonstrated its dedication to sustainability through various ESG achievements, including becoming a signatory to the United Nations Global Compact, receiving an AAA rating from MSCI ESG Ratings, and being awarded the EcoVadis Sustainability Rating's Platinum Medal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary
WuXi Biologics (2269.HK) has been awarded the EcoVadis Sustainability Rating's Platinum Medal, ranking in the top 1% of over 100,000 companies evaluated. The company has been recognized for outstanding performance across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, making it a trusted partner by global clients for its strong sustainability commitment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
-
Rhea-AI Summary
WuXi Biologics (2269.HK) has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale. The company achieved an average daily productivity of 6 g/L/day for a mAb molecule during the 18-day production phase, leading to a significantly high accumulated volumetric productivity at 105 g/L in the 25-day continuous cell culture process. The total yield calculated from Protein A capture to UF/DF reached nearly 80%, delivering over 3 kg protein from 40 L working volume. WuXi Biologics' end-to-end continuous DS manufacturing enabled by WuXiUPTM allows a 1,000 L disposable bioreactor to produce more than 60 kg of mAb per batch and approximately 800 kg per year, achieving productivity comparable to a traditional 10,000-20,000L bioreactor. The company aims to expedite biologics development, reduce the cost of goods (COGS) of commercial products, and increase operational flexibility due to minimal facility footprint utilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
Rhea-AI Summary
WuXi Biologics (2269.HK) has received an AAA rating from MSCI ESG Ratings, signaling outstanding performance in key ESG issues like climate change, corporate governance, talent development, and product safety & quality. This recognition solidifies WuXi Biologics' position as an industry leader in managing significant ESG opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
Rhea-AI Summary
WuXi Biologics launches WuXiUI™, a new proprietary bioprocessing platform that enhances productivity and reduces costs in biologics development and manufacture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
Rhea-AI Summary
WuXi Biologics congratulates Amicus Therapeutics on FDA approval for Pombiliti™ and Opfolda™ for late-onset Pompe disease. WuXi Biologics is the exclusive manufacturing partner for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
Rhea-AI Summary
WuXi Biologics reports solid business performance with sustained growth momentum and strong backlog
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
none
-
Rhea-AI Summary
WuXi Biologics and Boostimmune have signed a Memorandum of Understanding for research and discovery services. Boostimmune will have access to WuXi Biologics' integrated discovery services and expertise in antibody discovery. WuXi Biologics will be the exclusive service partner to support Boostimmune in generating different modality candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
-
Rhea-AI Summary
WuXi Biologics is expanding its manufacturing capacity in Germany in response to increasing demand for contract manufacturing services. The expansion includes the installation of a new drug product fill line at the Leverkusen site and a doubling of the biomanufacturing capacity at the Wuppertal site.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
Rhea-AI Summary

WuXi Biologics has been awarded the 2023 ISPE Facility of the Year Award (FOYA) in the Operations category for its manufacturing facility in Dundalk, Ireland. The facility, one of the largest of its kind in Europe, features two manufacturing areas with 6x1KL single-use bioreactors for perfusion and 12x4KL single-use bioreactors for fed-batch. Construction of the 467,500-square-foot greenfield facility began in December 2018 and operations started in December 2021, creating over 6,000 construction jobs and more than 500 highly skilled jobs in the region.

The facility received its first GMP certificate from the Irish Health Products Regulatory Authority (HPRA) just nine months after starting operations. In line with WuXi Biologics' ESG strategy, the site incorporates sustainable concepts, including 100% renewable energy power supply. This marks the second FOYA recognition for WuXi Biologics, following an Honorable Mention in 2014 for its facility in Wuxi city, China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none

FAQ

What is the current stock price of WUXI BIOLOGICS UNSP/ADR (WXXWY)?

The current stock price of WUXI BIOLOGICS UNSP/ADR (WXXWY) is $4.37 as of December 20, 2024.

What is the market cap of WUXI BIOLOGICS UNSP/ADR (WXXWY)?

The market cap of WUXI BIOLOGICS UNSP/ADR (WXXWY) is approximately 9.1B.

What services does WuXi Biologics provide?

WuXi Biologics offers a full range of services for biologics drug development, including discovery, development, and manufacturing solutions.

What are some of WuXi Biologics' notable achievements?

WuXi Biologics has contributed to the discovery of investigational monoclonal antibodies for leading companies, developed innovative platforms like WuXiBody™, and received recognition for their achievements in corporate transparency and sustainability.

How does WuXi Biologics support sustainability?

WuXi Biologics is committed to ESG leadership and sustainability, demonstrated through their use of next-generation biomanufacturing technologies, focus on water security, and recognition by global rating agencies for their sustainability efforts.

What technologies has WuXi Biologics developed?

WuXi Biologics has developed cutting-edge technologies like WuXiBody™ for bispecific constructs and WuXiaADCC PLUSTM for afucosylated antibodies, enhancing therapeutic efficacy and providing cost-effective manufacturing solutions.

How does WuXi Biologics innovate in biologics development?

WuXi Biologics fosters innovation through its drive to push boundaries, invest in next-generation technologies, and provide new biologics solutions for global partners, ultimately benefiting patients worldwide.

WUXI BIOLOGICS UNSP/ADR

OTC:WXXWY

WXXWY Rankings

WXXWY Stock Data

9.14B
2.05B
0%
Biotechnology
Healthcare
Link
United States of America
Wuxi